Anaplastic thyroid carcinoma: Treatment in the age of molecular targeted therapy

Abstract

Anaplastic thyroid carcinoma is one of the most aggressive and deadly cancers in humans and accounts for one to two cases per million persons annually. The rarity of this malignancy and the rapidity bywhich it grows has been amajor barrier to progress in finding effective therapies. Thus, the treatment that is the current standard of care for these patients is largely palliative, andfeware cured;however,novel therapies andapproaches are being studied in patients with anaplastic thyroid carcinoma and are delineated herein.